Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable insulin Clear all
Completed Phase 4 Interventional Results available

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00909480
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
71
States / cities
Litchfield Park, Arizona • Searcy, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

NCT02748018
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
25
States / cities
La Jolla, California • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

NCT01499082
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
95
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
View directory record Official record
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

A Study of t:Slim X2 With Control-IQ Technology

NCT03844789
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Control Group
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 13 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

NCT01334151
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Insulin LISPRO, recombinant human insulin
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management

NCT03676465
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CloudConnect Report, Will not receive a CloudConnect Report
Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT05539872
View directory record Official record
Conditions
Pharmacokinetics, Pharmacodynamics
Interventions
I004, NovoLog
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 22, 2026, 11:23 PM EDT
Terminated Phase 4 Interventional Results available

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

NCT00366301
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine injection, metformin, Placebo pill
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 3 Interventional

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
mibavademab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Hyperglycemia in Renal Transplantation

NCT01643382
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
Insulin, Insulin, Asp(B28)-
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 22, 2026, 11:23 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

NCT02496780
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
novolog insulin, levemir insulin, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 4 Interventional

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

NCT00384215
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
insulin glargine [rDNA origin] injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

NCT00743782
View directory record Official record
Conditions
Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Synthetic Human Parathyroid Hormone 1-34 pump
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
7 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Insulin Start Therapy Application With Resources and Training

NCT03999268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
I-START, Standard Insulin Administration Education
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 22, 2026, 11:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes

NCT00727220
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 5 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

NCT00910988
View directory record Official record
Conditions
Hyperglycemia, Hyperlipidemia
Interventions
Olanzapine, Ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Not yet recruiting Not applicable Interventional

Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction

NCT07165327
View directory record Official record
Conditions
Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
Interventions
Injection Port for Insulin Administration, Single-Use Insulin Needles
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 22, 2026, 11:23 PM EDT
Completed No phase listed Observational

Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

NCT01104142
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 22, 2026, 11:23 PM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.

NCT00596063
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Wosulin R, Novolin R
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 22, 2026, 11:23 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 22, 2026, 11:23 PM EDT